Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants

Abstract Aim Atezolizumab and bevacizumab (Atezo/Bev) combination immunotherapy regimens and direct oral anticoagulants (DOACs) are both associated with bleeding. Therefore, combining Atezo/Bev regimens with DOACs may exacerbate the bleeding risk. This study investigated the feasibility of the Atezo...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Tasuku Nakabori, Kei Kunimasa, Masaki Kawabata, Sena Higashi, Kaori Mukai, Takahisa Kawamura, Takako Inoue, Motohiro Tamiya, Kazumi Nishino, Kazuyoshi Ohkawa
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2024-06-01
Rangatū:	Cancer Medicine
Ngā marau:	atezolizumab and bevacizumab bleeding event combination immunotherapy direct oral anticoagulant hepatocellular carcinoma lung cancer
Urunga tuihono:	https://doi.org/10.1002/cam4.7430
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!